Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): June 18, 2020   Tenax Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Delaware   001-34600   26-2593535 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   ONE Copley Parkway, Suite 490 Morrisville, NC 27560 (Address of principal executive offices) (Zip Code)   919-855-2100 (Registrant’s telephone number, including area code)   N/A (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share TENX The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 5.07 Submission of Matters to a Vote of Security Holders.   Tenax Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 18, 2020 (the “Annual Meeting”). The stockholders considered the five proposals described below, each of which is described in more detail in the Company’s definitive proxy statement dated April 29, 2020 (the “Proxy Statement”). As of April 24, 2020, the record date for the Annual Meeting, there were 9,218,556 shares of common stock issued, outstanding and entitled to vote. At the Annual Meeting, 5,468,917   shares of common stock were represented in person or by proxy, constituting a quorum. The final number of votes cast for and against, as well as the number of abstentions and broker non-votes, with respect to each proposal are set forth below.   Proposal 1 : To elect the six director nominees described in the Proxy Statement to the Company’s Board of Directors to serve until the sooner of the 2021 Annual Meeting of the Company’s Stockholders or the election and qualification of their successors. The votes were cast as follows:     For   Withhold   Broker Non-Votes Ronald R. Blanck, DO 2,224,061   60,305   3,184,551 Anthony A. DiTonno 2,224,053   60,312   3,184,552 James Mitchum 2,224,057   60,308   3,184,552 Gregory Pepin 2,175,732   108,633   3,184,552 Gerald T. Proehl 2,224,053   60,312   3,184,552 Chris A. Rallis 2,224,057   60,308   3,184,552   All director nominees were duly elected.   Proposal 2 : To ratify the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020. The votes were cast as follows:   For   Against   Abstain 5,468,896   18   24   Proposal 2 was approved.     2     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Date: June 18, 2020 Tenax Therapeutics, Inc.                 By: /s/   Michael B. Jebsen     Michael B. Jebsen     President and Chief Financial Officer                   3